XXXXXXX MEETS LIVER KIDNEY - ILFTREATING HCV IN CKD PATIENTS: REACHING BEYOND THE LIVER Friday 16...

5
MEETS LIVER AMSTERDAM MARCH 16 th , 2018 XXXXXXX FINAL PROGRAM KIDNEY MEETS LIVER AMSTERDAM MARCH 16 th , 2018 When the excellence in renal and liver medicine come together.

Transcript of XXXXXXX MEETS LIVER KIDNEY - ILFTREATING HCV IN CKD PATIENTS: REACHING BEYOND THE LIVER Friday 16...

Page 1: XXXXXXX MEETS LIVER KIDNEY - ILFTREATING HCV IN CKD PATIENTS: REACHING BEYOND THE LIVER Friday 16 March, 12:45–13:45 Location: Taurus 2 Exploring the clinical consequences of HCV

KIDNEYM E E T SL I V E R

AMSTERDAM MARCH 16th, 2018

When the excellence in renal and liver medicine come together.

1

XXXXXXX

FINAL PROGRAM

KIDNEYM E E T SL I V E R

AMSTERDAM MARCH 16th, 2018

When the excellencein renal and liver medicine

come together.

Page 2: XXXXXXX MEETS LIVER KIDNEY - ILFTREATING HCV IN CKD PATIENTS: REACHING BEYOND THE LIVER Friday 16 March, 12:45–13:45 Location: Taurus 2 Exploring the clinical consequences of HCV

FINAL PROGRAM KIDNEYM E E T SL I V E R

AMSTERDAM MARCH 16th, 2018

When the excellence in renal and liver medicine come together.

2 3

SCIENTIFIC PROGRAMCOMITATI

Organizing Committee

Prof. Michel JadoulChief Service de NephrologieClinique Universitaire Saint-Luc

Bruxelles, Belgium

Prof. Paul MartinChief Gastroenterology and Hepatology

Miller School of Medicine,University of Miami, USA

Prof. Stanislas PolChief Gastro-Enterology and Hepatology, Cochin Hospital

and Universitè Paris V (Paris Descartes)Paris, France

Introduction and welcome M. Jadoul (Bruxelles, Belgium), P. Martin (Miami, USA), S. Pol (Paris, France)

08.30-10.00 Session 1 HCV and CKD : Epidemiology and reciprocal impacts Chairs: S. Pol (Paris, France), N. Kamar (Toulouse, France)

HCV: an evolving epidemiology J. Lazarus (Barcelona, Spain)

CKD: the current global epidemiology Z. Massy (Paris, France)

HCV: epidemiology in CKD populations M. Jadoul (Bruxelles, Belgium)

HCV: impact (morbi/morta/QoL) of HCV F. Fabrizi (Milan, Italy) in HD and renal transplant

HCV: diagnostic and prognostic workup L.D. Castera (Clichy, France)including non-invasive evaluation of fibrosis

HCV: a bad player acting beyond the liver (includes CKD progression and CV risk) A. Bruchfeld (Stockholm, Sweden)

10.00-10.15 Coffee breakOrganizing Secretariat

Via Enrico Mattei, 92 - 40138 Bologna, ItalyPhone +39 0514595093 - E-mail [email protected] - www.euromeetings.it

EASL-ILFInternational Liver Foundation

www.easl-ilf.org

ERA-EDTAEuropean Renal Association –

European Dialysis and Transplant Associationwww.era-edta.org

Organized by

Page 3: XXXXXXX MEETS LIVER KIDNEY - ILFTREATING HCV IN CKD PATIENTS: REACHING BEYOND THE LIVER Friday 16 March, 12:45–13:45 Location: Taurus 2 Exploring the clinical consequences of HCV

FINAL PROGRAM KIDNEYM E E T SL I V E R

AMSTERDAM MARCH 16th, 2018

When the excellence in renal and liver medicine come together.

4 5

15.30-17.00 Session 4 Let us fight together the obesity / metabolic syndrome epidemic Chairs: L. Serfaty (Paris, France), C. Zoccali (Reggio Calabria, Italy)

Lipid profile and management in CKD and NAFLD A. Jardine (Glasgow, United Kingdom)

Interactions between the liver and the gut : involvement of the microbiome G. Perlemuter (Paris, France)

Recent and emerging therapies for diabetic G. Mayer (Innsbuck, Austria)nephropathy NAFLD: an emerging challenge in CKD patients P. Kalra (Salford, United Kingdom)

Emerging therapies for NAFLD L. Serfaty (Paris, France)

Concluding remarks P. Martin (Miami, USA), C. Zoccali (Reggio Calabria, Italy)

10.15-11.45 Session 2HCV management and preventionChairs: S. Badalamenti (Milan, Italy), M. C. Londoño (Barcelona, Spain)

HCV: current status of antiviral therapy S. Pol (Paris, France)in the respective CKD populations P. Martin (Miami, USA)

HCV: prevention of HCV in HD M. Jadoul (Bruxelles, Belgium)

Hepatocellular carcinoma screening M. C. Londoño (Barcelona, Spain)in CKD populations

11.45-12.45 Lunch Symposium 1

12.45-13.45 Lunch Symposium 2

13.45-15.15 Session 3 Round table: ”HCV - Bridging the gap between treatment evidenceand real world in the various CKD populations”Moderator: S. Pol (Paris, France)All present experts

15.15-15.30 Coffee break

SCIENTIFIC PROGRAMSCIENTIFIC PROGRAM

Page 4: XXXXXXX MEETS LIVER KIDNEY - ILFTREATING HCV IN CKD PATIENTS: REACHING BEYOND THE LIVER Friday 16 March, 12:45–13:45 Location: Taurus 2 Exploring the clinical consequences of HCV

FINAL PROGRAM KIDNEYM E E T SL I V E R

AMSTERDAM MARCH 16th, 2018

When the excellence in renal and liver medicine come together.

6 7

GENERAL PROGRAM

AGENDA

FRIDAY, 16 MARCH 2018 11:45 – 12:45

LEADERSHIP • COMMITMENT • INNOVATIONMore Than 30 Years of Innovation and Commitment to Patients With Chronic Hepatitis C Virus (HCV) Infection

TO TREAT OR NOT TO TREAT HCV IN CKD, THAT IS THE QUESTION:

AN INTERACTIVE DISCUSSION

Copyright © 2018 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. All rights reserved. ZEP-198239-IN

Novotel Amsterdam Schiphol Airport • Room: Taurus 2 Amsterdam, Netherlands

CHAIRMaría LondoñoUniversity of Barcelona Barcelona, Spain

FACULTYMichel JadoulHead, Department of NephrologyCliniques Universitaires Saint-Luc Service de NephrologieBrussels, Belgium

Stanislas PolService Hépatologie Médicale Hôpital Cochin Paris, France

11:45 – 11:55 Welcome and Opening Remarks María Londoño

11:55 – 12:10 HCV in a Patient With Advanced CKD: Too Late to Treat?

Michel Jadoul Stanislas Pol

12:10 – 12:25 HCV in a Patient With Moderate CKD: Too Soon to Treat?

Michel Jadoul María Londoño

12:25 – 12:40 Screening and Linkage to Care: A Call to Action

Faculty

12:40 – 12:45 Q&A and Closing Remarks Faculty

1st Kidney Meets Liver Meeting

Friday, 16 March 2018 • Amsterdam, Netherlands

YOU’RE INVITED!

TREATING HCV IN CKD PATIENTS: REACHING BEYOND THE LIVER

Friday 16 March, 12:45–13:45 Location: Taurus 2

Exploring the clinical consequences of HCV infection in CKD populations and discussing regimens available to treat HCV in CKD

AgendaWelcome and Introduction Prof. Stanislas Pol (Chair)The Extrahepatic Manifestations of HCV Prof. Patrice CacoubTreatment for HCV in CKD Prof. Paul MartinAudience Q&A and Summary Prof. Stanislas Pol

Kidney Meets Liver: Amsterdam, March 16, 2018

Page 5: XXXXXXX MEETS LIVER KIDNEY - ILFTREATING HCV IN CKD PATIENTS: REACHING BEYOND THE LIVER Friday 16 March, 12:45–13:45 Location: Taurus 2 Exploring the clinical consequences of HCV

Congress VenueNovotel Amsterdam Schiphol AirportTaurusavenue 12 2132 LS Hoofddorp Nederlandhttps://www.accorhotels.com/it/hotel-7060-novotel-amsterdam-schiphol-airport/index.shtml

RegistrationYou can register here http://www.euromeetings.it/EILFAmsterdam2018.html or direclty in Amsterdam at Novotel Schiphol starting March 15 from 3 to 8 pm.Cost of the registration: euro 550

UEMS CME creditsThe event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 6 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Certificate of attendanceThe certificate of attendance will be sent to all regularly registered delegates by email after the congress

GENERAL INFORMATION


Expression of NS4 HCV in liver cells of HIV/HCV co ...regist2.virology-education.com/2016/2CEE/19_Matsiyeuskaya.pdf · NS4 HCV • NS4 HCV: NS4A and NS4B • NS4A protein is a 54

Expression of NS4 HCV in liver cells of HIV/HCV co ...regist2.virology-education.com/2016/2CEE/19_Matsiyeuskaya.pdf · NS4 HCV • NS4 HCV: NS4A and NS4B • NS4A protein is a 54

Treatment for HCV Infection HHS Public Access Mei Lu ...hepatitis C virus (HCV) correlates with changes in biochemical measures of liver function. However, little is known about the

Treatment for HCV Infection HHS Public Access Mei Lu ...hepatitis C virus (HCV) correlates with changes in biochemical measures of liver function. However, little is known about the

Management of Chronic HCV Cirrhosis: Pre and Post-Liver ... · PDF fileManagement of Chronic HCV Cirrhosis: Pre and Post-Liver Transplantation K.Rajender Reddy M.D., Professor of Medicine

Management of Chronic HCV Cirrhosis: Pre and Post-Liver ... · PDF fileManagement of Chronic HCV Cirrhosis: Pre and Post-Liver Transplantation K.Rajender Reddy M.D., Professor of Medicine

Diagnosis. Multifactorial pathogenesis of HCC Normal liver HepatitisCirrhosisHCC Cell death Regeneration Persistent/chronic hepatitis Fibrosis HBV HCV.

Diagnosis. Multifactorial pathogenesis of HCC Normal liver HepatitisCirrhosisHCC Cell death Regeneration Persistent/chronic hepatitis Fibrosis HBV HCV.

CD40 polymorphisms were associated with HCV infection ......important effect on antiviral immune response. In HCV-associated chronic liver diseases, CD40 is highly expressed on liver

CD40 polymorphisms were associated with HCV infection ......important effect on antiviral immune response. In HCV-associated chronic liver diseases, CD40 is highly expressed on liver

HCV-HIV Coinfection: Pathogenesis of Accelerated Liver ...regist2.virology-education.com › 2015 › 11COINFECTION › 15_Chung.… · HCV-HIV Coinfection: Pathogenesis of Accelerated

HCV-HIV Coinfection: Pathogenesis of Accelerated Liver ...regist2.virology-education.com › 2015 › 11COINFECTION › 15_Chung.… · HCV-HIV Coinfection: Pathogenesis of Accelerated

British Liver Transplant Group Pathology meeting September · PDF file · 2014-10-07British Liver Transplant Group Pathology meeting ... Liver transplant for HCV cirrhosis with HCC

British Liver Transplant Group Pathology meeting September · PDF file · 2014-10-07British Liver Transplant Group Pathology meeting ... Liver transplant for HCV cirrhosis with HCC

LA GESTIONE GLOBALE - Centro Nazionale Sangue · •HCV patients with advanced disease: HCC screen and evaluation for liver transplantation (OLT) •Non invasive assessment of liver

LA GESTIONE GLOBALE - Centro Nazionale Sangue · •HCV patients with advanced disease: HCC screen and evaluation for liver transplantation (OLT) •Non invasive assessment of liver

Molecular Signatures Associated with HCV-Induced ...Molecular Signatures Associated with HCV-Induced Hepatocellular Carcinoma and Liver Metastasis Valeria De Giorgi2*, Luigi Buonaguro1,

Molecular Signatures Associated with HCV-Induced ...Molecular Signatures Associated with HCV-Induced Hepatocellular Carcinoma and Liver Metastasis Valeria De Giorgi2*, Luigi Buonaguro1,

Rheumatological Manifestations Associated with Viral ... · inhabitants) and similar for HCV (12.9/100,000 inhabitants)3. The HBV and HCV infections primarily affect the liver; nevertheless,

Rheumatological Manifestations Associated with Viral ... · inhabitants) and similar for HCV (12.9/100,000 inhabitants)3. The HBV and HCV infections primarily affect the liver; nevertheless,

The Impact of Curing HCV on the Liver and the Extra ...s3.gi.org/meetings/mn2016/16ACG_Hep_School_Midwest_0013.pdf · IVer Bon Secours Health System The Impact of Curing HCV on the

The Impact of Curing HCV on the Liver and the Extra ...s3.gi.org/meetings/mn2016/16ACG_Hep_School_Midwest_0013.pdf · IVer Bon Secours Health System The Impact of Curing HCV on the

Hepatitis C - NPAIHBUIC Hepatitis C Clinic Inpatient liver service JPS Hospital, Fort Worth Texas: Healing Wings HIV Clinic ... (HCV RNA positive) More people dying of HCV than all

Hepatitis C - NPAIHBUIC Hepatitis C Clinic Inpatient liver service JPS Hospital, Fort Worth Texas: Healing Wings HIV Clinic ... (HCV RNA positive) More people dying of HCV than all

ORIGINAL ARTICLE Characterisation of liver …ORIGINAL ARTICLE Characterisation of liver pathogenesis, human immune responses and drug testing in a humanised mouse model of HCV infection

ORIGINAL ARTICLE Characterisation of liver …ORIGINAL ARTICLE Characterisation of liver pathogenesis, human immune responses and drug testing in a humanised mouse model of HCV infection

HCV Highlights from AASLD 2012 - Chronic Liver Disease Foundation

HCV Highlights from AASLD 2012 - Chronic Liver Disease Foundation

Molecular interactions between alcohol, hepatitis C virus ...€¦ · Figure 1.1 Clinical spectrum of HCV infection 3 Figure 1.2 Progression of HCV induced liver disease 3 Figure

Molecular interactions between alcohol, hepatitis C virus ...€¦ · Figure 1.1 Clinical spectrum of HCV infection 3 Figure 1.2 Progression of HCV induced liver disease 3 Figure

Cancer and end stage organ disease in HIV-infected individuals€¦ · HIV and liver transplant: HCV/HIV •HCV is the #1 reason for liver transplant in US •Even if our efforts

Cancer and end stage organ disease in HIV-infected individuals€¦ · HIV and liver transplant: HCV/HIV •HCV is the #1 reason for liver transplant in US •Even if our efforts

Impact of Direct Acting Antivirals on Survival in Patients ... · 85Hepatitis C (HCV), and non-alcoholic fatty liver disease.1 86Chronic HCV infection is the second most common risk

Impact of Direct Acting Antivirals on Survival in Patients ... · 85Hepatitis C (HCV), and non-alcoholic fatty liver disease.1 86Chronic HCV infection is the second most common risk

(Z)-3,5,4 -Trimethoxystilbene Limits Hepatitis C and Cancer … · HCV also induces EGFR that facilitates HCV entry into the cells and promotes progression of liver diseases (20,

(Z)-3,5,4 -Trimethoxystilbene Limits Hepatitis C and Cancer … · HCV also induces EGFR that facilitates HCV entry into the cells and promotes progression of liver diseases (20,

TheHepatitisCVirus-inducedNLRP3Inflammasome … · 2018-12-11 · to liver disease pathogenesis associated with chronic HCV. Chronic liver disease resulting from HCV infection repre-sentsamajorglobalhealthproblem.HCVinfectionoftenleads

TheHepatitisCVirus-inducedNLRP3Inflammasome … · 2018-12-11 · to liver disease pathogenesis associated with chronic HCV. Chronic liver disease resulting from HCV infection repre-sentsamajorglobalhealthproblem.HCVinfectionoftenleads

Www.ias2015.org Liver fibrosis regression after anti HCV therapy and the rate of death, liver-related death, liver- related complications, and hospital.

Www.ias2015.org Liver fibrosis regression after anti HCV therapy and the rate of death, liver-related death, liver- related complications, and hospital.